UniProt G3G192
Beta-lactamase (G3G192)
Beta-lactamase (UniProt G3G192), EC 3.5.2.6: 27 experimental structures on GenesisL1, 11 ligands bound, 14 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- G3G192
- Protein
- Beta-lactamase
- EC
- 3.5.2.6
- Experimental structures
- 27
- Predicted models
- 0
- Ligands
- 11
- Pockets
- 14 · 0 records with a druggable one
Structures
27 records of G3G192 in the MolNFT archive: 27 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 4S2I | CTX-M-15 in complex with Avibactam | x-ray diffraction | A, B | — | — |
| 4S2I | Ctx-M-15 in complex with avibactam | x-ray diffraction | A, B | — | — |
| 5T66 | Crystal structure of ctx-M-15 with 1C | x-ray diffraction | A, B | C6S | — |
| 6QW8 | Crystal structure of CTX-M-15 complexed with relebactam (16 hour soak) | x-ray diffraction | A | MK7, SO4 | 1 (best 0.35) |
| 6QW8 | Crystal structure of ctx-M-15 complexed with relebactam (16 hour soak) | x-ray diffraction | A | MK7, SO4 | — |
| 6Z7I | Crystal structure of CTX-M-15 E166Q mutant apoenzyme | x-ray diffraction | A | SO4 | 1 (best 0.34) |
| 6Z7I | Crystal structure of ctx-M-15 E166Q mutant apoenzyme | x-ray diffraction | A | SO4 | — |
| 6Z7K | Crystal structure of CTX-M-15 in complex with the imine form of hydrolysed tazobactam | x-ray diffraction | A | QBZ, SO4, CL | 1 (best 0.29) |
| 6Z7K | Crystal structure of ctx-M-15 in complex with the imine form of hydrolysed tazobactam | x-ray diffraction | A | QBZ, SO4, CL | — |
| 7BH3 | XFEL structure of CTX-M-15 resting state | x-ray diffraction | A | SO4, CL | 1 (best 0.33) |
| 7BH3 | Xfel structure of ctx-M-15 resting state | x-ray diffraction | A | SO4, CL | — |
| 7BH4 | XFEL structure of apo CTX-M-15 after mixing for 0.7 sec with ertapenem using a piezoelectric… | x-ray diffraction | A | SO4 | 1 (best 0.31) |
| 7BH4 | Xfel structure of apo ctx-M-15 after mixing for 0.7 sec with ertapenem using a piezoelectric… | x-ray diffraction | A | SO4 | — |
| 7BH5 | XFEL structure of the ertapenem-derived CTX-M-15 acylenzyme after mixing for 2 sec using a… | x-ray diffraction | A | TVE, CL, NA | 1 (best 0.33) |
| 7BH5 | Xfel structure of the ertapenem-derived ctx-M-15 acylenzyme after mixing for 2 sec using a… | x-ray diffraction | A | TVE, CL, NA | — |
| 7BH6 | Room temperature, serial X-ray structure of CTX-M-15 collected on fixed target chips at Diamond… | x-ray diffraction | A | SO4, CL, NA | 1 (best 0.32) |
| 7BH6 | Room temperature, serial X-ray structure of ctx-M-15 collected on fixed target chips at diamond… | x-ray diffraction | A | SO4, CL, NA | — |
| 7BH7 | Room temperature, serial X-ray structure of the ertapenem-derived acylenzyme of CTX-M-15 (10 min… | x-ray diffraction | A | TVE, CL, NA | 1 (best 0.32) |
| 7BH7 | Room temperature, serial X-ray structure of the ertapenem-derived acylenzyme of ctx-M-15 (10 min… | x-ray diffraction | A | TVE, CL, NA | — |
| 7R3Q | Crystal structure of CTX-M-15 G238C/A240 insert mutant apoenzyme | x-ray diffraction | A | SO4, CL | 1 (best 0.30) |
| 7R3Q | Crystal structure of ctx-M-15 G238C/A240 insert mutant apoenzyme | x-ray diffraction | A | SO4, CL | — |
| 7R3R | Crystal structure of CTX-M-15 G238C mutant apoenzyme | x-ray diffraction | A | SO4, CL | 1 (best 0.31) |
| 7R3R | Crystal structure of ctx-M-15 G238C mutant apoenzyme | x-ray diffraction | A | SO4, CL | — |
| 8R2Y | Structure of CTX-M-15 complexed with benzoxaborole AK-29 | x-ray diffraction | A | 6M9, SO4, CL, NA | 1 (best 0.34) |
| 8R2Z | Structure of CTX-M-15 complexed with benzoxaborole AK-425 | x-ray diffraction | A | XR9, SO4, CL, NA | 1 (best 0.32) |
| 8R30 | Structure of CTX-M-15 complexed with benzoxaborole AK-408 | x-ray diffraction | A | XR3, SO4, CL, NA | 1 (best 0.35) |
| 8R31 | Structure of CTX-M-15 complexed with benzoxaborole AK-412 | x-ray diffraction | A | XQN, SO4, CL, NA | 1 (best 0.32) |
Ligands
- SO4 · Sulfate ion · in 20 records
- CL · Chloride ion · in 18 records
- NA · Sodium ion · in 10 records
- TVE · (2~{S},3~{R},4~{R})-3-[5-[(3-carboxyphenyl) carbamoyl]pyrrolidin-3-yl]sulfanyl-4-methyl-5-[(2~{S}, 3~{R})-3-oxidanyl-1-oxidanylidene-butan-2-yl]-3,4-dihydro-2~{H}-pyrrole-2-carboxylic acid · in 4 records
- MK7 · (2S,5R)-1-formyl-N-(piperidin-4-yl)-5-[(sulfooxy) amino]piperidine-2-carboxamide · in 2 records
- QBZ · (2~{S},3~{S})-3-[bis(oxidanylidene)-$l^{5}-sulfanyl]-3-methyl-2-[(~{E})-3-oxidanylidenepropylideneamino]-4-(1,2,3-triaz ol-1-yl)butanoic acid · in 2 records
- 6M9 · 2,1-benzoxaborol-1(3H)-ol · in 1 record
- C6S · (3R)-3-(cyclohexylcarbonylamino)-2-oxidanyl-3,4-dihydro-1,2-benzoxaborinine-8-carboxylic acid · in 1 record
- XQN · 4-chloranyl-N-[[(3S)-1-oxidanyl-3H-2,1$l^{4}-benzoxaborol-3-yl]methyl]benzenesulfonamide · in 1 record
- XR3 · N-[[(3S)-1-oxidanyl-3H-2,1-benzoxaborol-3-yl]methyl]-4-[oxidanyl(oxidanylidene)-$l^{4}-azanyl]benzenesulfonamide · in 1 record
- XR9 · (9S)-7-oxidanyl-8-oxa-7-boranuidabicyclo[4.3.0]nona-1,3,5-triene-9-carbonitrile · in 1 record
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.